Billable / Specific Code
ICD-10-CM C88.81 is the diagnosis code for Other malignant immunoproliferative diseases, in remission. This code falls under the section "Malignant neoplasms of lymphoid, hematopoietic and related tissue" within Chapter 2 — Neoplasms (C00-D49). It is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. Medical coders and healthcare providers use this code to document and classify diagnoses in electronic health records, insurance claims, and clinical databases.
Always refer to the official ICD-10-CM Tabular List for complete coding guidelines. Ensure documentation supports the specificity of the code selected. When in doubt, consult a certified medical coder or the latest CMS guidelines.
Understanding where C88.81 sits in the ICD-10-CM classification helps ensure proper coding:
Yes, C88.81 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
C88.81 is the ICD-10-CM diagnosis code for "Other malignant immunoproliferative diseases, in remission". It is used by healthcare providers to classify and document this condition in medical records and insurance claims.
The parent code of C88.81 is C88.8 ("Other malignant immunoproliferative diseases"). C88.81 provides a more specific classification within this category.
C88.81 is located in Section C81-C96 — "Malignant neoplasms of lymphoid, hematopoietic and related tissue" within Chapter 2 of the ICD-10-CM Tabular List.
Use C88.81 when the patients documented diagnosis matches "Other malignant immunoproliferative diseases, in remission" and the clinical documentation supports this level of specificity. Always verify with the latest ICD-10-CM guidelines and payer requirements.
The ICD-10-CM code for Other malignant immunoproliferative diseases, in remission is C88.81.
Yes, C88.81 can be used as a primary diagnosis code since it is billable and specific.
C88.81 is in Chapter 2 of the ICD-10-CM Tabular List.
Yes, C88.81 is a valid ICD-10-CM code for the 2026 fiscal year, subject to official CMS updates.